Payment overview · 2025
General Payments
$727.39
54 reported records · 10 companies
Healthcare provider profile · identity verified
Teresa Gray, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BARBOURVILLE, KY · NPI 1891050779
Verified facts
What the public records show
CMS Open Payments records show Teresa Gray, APRN received $727.39 in general payments during 2025 across 54 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Farxiga, Qulipta, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Caplyta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $191.85 | 26.4% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.76 | 21.6% | 21 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $88.90 | 12.2% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $78.90 | 10.8% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $65.33 | 9.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.54 | 7.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.11 | 4.7% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $23.60 | 3.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.81 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.59 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.39 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $134.81 | 17 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.17 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $115.59 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $106.20 | 15 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $105.21 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $100.38 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $88.90 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $78.90 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $65.33 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.54 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.11 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.95 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1024 | 116 |
| Ibuprofen | Ibuprofen | 432 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 378 | 53 |
| Clonidine Hcl | Clonidine Hcl | 374 | 44 |
| Lisinopril | Lisinopril | 372 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 232 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 27 |
| Omeprazole | Omeprazole | 205 | 27 |
| Clonazepam | Clonazepam | 204 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 43 |
| Metformin Hcl | Metformin Hcl | 197 | 28 |
| Potassium Chloride | Potassium Chloride | 194 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 169 | 29 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 167 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 166 | 21 |
| Ondansetron Odt | Ondansetron | 163 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 152 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 150 | 17 |
| Meloxicam | Meloxicam | 149 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 149 | 27 |
| Famotidine | Famotidine | 146 | 17 |
| Losartan Potassium | Losartan Potassium | 144 | 18 |
| Prednisone | Prednisone | 144 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 138 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 136 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 116 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 15 |
| Carvedilol | Carvedilol | 110 | 17 |
| Furosemide | Furosemide | 107 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 106 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 13 |
| Promethazine Hcl | Promethazine Hcl | 104 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 11 |
| Atenolol | Atenolol | 96 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 93 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | suppressed |
| Levetiracetam | Levetiracetam | 84 | suppressed |
| Nitroglycerin | Nitroglycerin | 82 | 13 |
| Meclizine Hcl | Meclizine Hcl | 81 | 11 |
| Mirtazapine | Mirtazapine | 81 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 80 | suppressed |
| Simvastatin | Simvastatin | 76 | suppressed |
| Naproxen | Naproxen | 70 | suppressed |
| Ozempic | Semaglutide | 70 | suppressed |
| Celecoxib | Celecoxib | 67 | 11 |
| Topiramate | Topiramate | 64 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 62 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 59 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 59 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 58 | suppressed |
| Allopurinol | Allopurinol | 56 | suppressed |
| Methylprednisolone | Methylprednisolone | 54 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | suppressed |
| Linzess | Linaclotide | 51 | suppressed |
| Nystatin | Nystatin | 51 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 50 | suppressed |
| Cephalexin | Cephalexin | 49 | 27 |
| Prazosin Hcl | Prazosin Hcl | 49 | suppressed |
| Fenofibrate | Fenofibrate | 47 | suppressed |
| Fluconazole | Fluconazole | 47 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Eliquis | Apixaban | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 20 |
| Mupirocin | Mupirocin | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Colchicine | Colchicine | 40 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 23 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Caplyta | Lumateperone Tosylate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 18 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 27 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Glyburide | Glyburide | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 20 |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Diazepam | Diazepam | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Permethrin | Permethrin | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Methazolamide | Methazolamide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cimetidine | Cimetidine | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.39 · 54 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, NURTEC ODT, Ohtuvayre, QULIPTA, REXULTI, SUBLOCADE, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error